BAVA Share Price Performance
DKK 0
-208.60 (-100.00%)
Price DKK 0
Fair ValueDKK 225.00
Share Pricen/a
Bavarian Nordic A/S Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 42 Fair Values set on narratives written by author
BAVA Community Narratives
AN
Fair Value DKK 225 15.8% undervalued intrinsic discount
Dependence On Key Contracts Will Hamper Performance Yet Suggest Promise
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value DKK 244 22.4% undervalued intrinsic discount
Rising Global Vaccine Demand Will Spur Progress But Face Headwinds
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value DKK 250 24.3% undervalued intrinsic discount
Local Spread Of New Mpox Strain Will Challenge Future Vaccine Margins
0users have liked this narrative
0users have commented on this narrative
30users have followed this narrative
Local Spread Of New Mpox Strain Will Challenge Future Vaccine Margins
Key Takeaways Heavy reliance on short-term vaccine demand and a narrow product mix poses risks to revenue stability and earnings predictability as conditions normalize. Rising pricing pressures, market access limitations, and regulatory uncertainties threaten profit margins and could undermine optimistic growth expectations.Read more
0users have liked this narrative
0users have commented on this narrative
30users have followed this narrative
AN
DKK 250
24.3% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
-3.46% p.a.
Profit Margin
15.82%
Future PE
23.92x
Share price in 2028
DKK 287.34
Dependence On Key Contracts Will Hamper Performance Yet Suggest Promise
Key Takeaways Reliance on government contracts and a few high-value vaccines makes future revenues vulnerable to shifting spending priorities and competitive pressures. Manufacturing, regulatory, and demand uncertainties could cause volatile earnings and prevent expected margin improvements, despite efforts to diversify and scale operations.Read more
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
DKK 225
15.8% undervalued intrinsic discount
AnalystLowTarget Fair Value
Revenue growth
-4.17% p.a.
Profit Margin
14.35%
Future PE
24.42x
Share price in 2028
DKK 259.42
Rising Global Vaccine Demand Will Spur Progress But Face Headwinds
Key Takeaways Accelerated manufacturing and strong travel health performance suggest margins and revenues may surpass expectations, signaling potential for significant long-term upside. Unique vaccine capabilities and expanding portfolio position the company to benefit from global health trends and increasing market opportunities, driving superior operational and financial growth.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
DKK 244
22.4% undervalued intrinsic discount
AnalystHighTarget Fair Value
Revenue growth
-2.34% p.a.
Profit Margin
14.48%
Future PE
24.81x
Share price in 2028
DKK 281.33
Snowflake Analysis
Bavarian Nordic A/S Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Nov 14, 2025
- 18.18
- 53.10%
- 22.04%
- 0.1%
About BAVA
- Founded
- 1992
- Employees
- 1667
- CEO
- WebsiteView website
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, Finland, Netherlands, Switzerland, Sweden, Taiwan, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
